Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay.

[1]  D. Pillay,et al.  The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy , 2009, AIDS.

[2]  C. Charpentier,et al.  Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure , 2009, Antimicrobial Agents and Chemotherapy.

[3]  V. Calvez,et al.  Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. , 2009, The Journal of antimicrobial chemotherapy.

[4]  R. Swanstrom,et al.  Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia , 2009, PLoS pathogens.

[5]  Olga M. Klibanov,et al.  Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. , 2009, Current opinion in investigational drugs.

[6]  C. Carter,et al.  Cell biology of HIV-1 infection of macrophages. , 2008, Annual review of microbiology.

[7]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[8]  Yves Pommier,et al.  Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. , 2008, Biochemistry.

[9]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[10]  A. Zolopa,et al.  Integrase inhibitors: a clinical review of raltegravir and elvitegravir. , 2008, Journal of HIV therapy.

[11]  Michael Rowley,et al.  Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. , 2007, Journal of medicinal chemistry.

[12]  D. Hazuda,et al.  Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. , 2007, Journal of medicinal chemistry.

[13]  A. Antinori,et al.  Mechanisms underlying activity of antiretroviral drugs in HIV‐1‐infected macrophages: new therapeutic strategies , 2006, Journal of leukocyte biology.

[14]  Y. Pommier,et al.  Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds , 2006, Antimicrobial Agents and Chemotherapy.

[15]  A. Cara,et al.  Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. , 2005, The Journal of general virology.

[16]  W. Robinson,et al.  Human Immunodeficiency Virus Type 1 (HIV-1) Integrase: Resistance to Diketo Acid Integrase Inhibitors Impairs HIV-1 Replication and Integration and Confers Cross-Resistance to l-Chicoric Acid , 2004, Journal of Virology.

[17]  R. Testi,et al.  Primary macrophages infected by human immunodeficiency virus trigger CD95‐mediated apoptosis of uninfected astrocytes , 2000, Journal of leukocyte biology.

[18]  G. Sauer.  Die Molekularbiologie der Tumorviren , 1977, Naturwissenschaften.

[19]  B. Thiers.  Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection , 2009 .

[20]  T. Chou,et al.  Synergism and antagonism in chemotherapy , 1991 .

[21]  H. Varmus,et al.  Molecular biology of tumor viruses. RNA tumor viruses. , 1982 .

[22]  A. Bernstein,et al.  RNA tumor viruses , 1982 .